Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 17, 2020
Daily News
November 17, 2020
- Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review
November 17, 2020
- Experts Urge Transparency for DPO/CEA Organization, Stringent Pricing for Cost-Based Products: Govt Project Review
November 17, 2020
- Eisai’s Fycompa Gets Pediatric Nod in Europe
November 17, 2020
- Janssen Resumes Japan PI for COVID-19 Vaccine after Temporary Pause
November 17, 2020
- Shionogi Forms Consortium with Univ. of Cambridge, AZ for Digitalized Chemical Synthesis
November 17, 2020
- Medicago, GSK Commence PII of Adjuvanted COVID-19 Vaccine, Progressing into PIII during December
November 17, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…